載入...
A Phase II Trial of Osimertinib in the Second-Line Treatment of Non-small Cell Lung Cancer with the EGFR T790M Mutation, Detected from Circulating Tumor DNA: LiquidLung-O-Cohort 2
PURPOSE: Administering the best treatment after failure of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) therapy requires knowledge of resistance status. In this trial, treatment efficacy of osimertinib was assessed in patients with non-small cell lung carcinoma (NSCLC) har...
Na minha lista:
| 發表在: | Cancer Res Treat |
|---|---|
| Main Authors: | , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Korean Cancer Association
2019
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6473264/ https://ncbi.nlm.nih.gov/pubmed/30189719 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4143/crt.2018.387 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|